🐾 PET RESCUERS 🐾 SCAN ANGELS 🐾 ANIMAL LAW 🐾 SOLENSIA
1. Solensia - Veterinary Experts' Insights, Medical Articles
Dr. Judy Morgan’s Naturally Healthy Pets - Solensia💉Pain Management for Cats with Osteoarthritis⚠️Potential Risks & Side Effects
October 6, 2024
Get savvy about the risks of monoclonal antibody injections, uncover the secret ways our feline friends hide symptoms 😺, and educate yourself on possible side effects. Just the right video for smart pet parents on a mission to keep their fur babies healthy! 🐾🐶🐱🐾
The Pet Quarter Dog and Cat Nutrition - 5 Deadly Veterinary Drugs (Protect Your Pet)
September 14, 2024
Sam is going through 5 deadly veterinary drugs, with Solensia being one of them.
Veterinary Secrets - What's the REAL Truth About Librela and Solensia Injections for Pets?
September 11, 2024
Are monthly arthritis injections like Librela for dogs and Solensia for cats the right choice for your pet's arthritis management? In this detailed video, Dr. Andrew Jones dives deep into the pros and cons of these popular treatments. Discover the potential risks associated with Librela and Solensia, and why you might want to consider safer, holistic alternatives for your furry friends. Dr. Jones will discuss all-natural solutions that can relieve arthritis pain without the harsh side effects. Stay tuned to make the best health decision for your pet! ✨🌿
Dr Matt Parker Holistic Functional Veterinarian -
September 6, 2024
Solensia for Cats & Librela for Dogs: How they work & Why they are wrong, and Why your veterinarian often makes the wrong choice.
The Pet Quarter Dog and Cat Nutrition - a heartbreaking solensia tale
August 29, 2024
Sam tells the heartbreaking story of one of our Group Members, Kelly.
Pet Advocare: A Voice For Companion Animals - Help for dealing with side effects from Librela® and Beransa® for dogs and Solensia® for cats
August 19, 2024
Dr. Josie has been on the vanguard of the concerns about Librela and Solensia since its arrival on the U.S. market in October of 2023. In this video she provides detailed explanations about what is happening to pets suffering adverse reactions, the critical roles of NGF in the body, is it possible to detox your pet, how you can best help your pet in pursuit of recovery.
The Pet Quarter Dog and Cat Nutrition - 🔴 ZOETIS CEO ADDRESSES LIBRELA SAFETY ISSUES 🔴
May 24, 2024
Sam goes through the interview that Zoetis CEO had given, in which she was addressing safety concerns (ergo bunch of lies from Zoetis).
The Pet Quarter Dog and Cat Nutrition - WSJ Report on DEADLY ZOETIS ARTHRITIS DRUGS for Pets - Librela and Solensia
April 12, 2024
A Wall Street Journal report suggested the company's arthritis shots, Librela and Solensia, could have sickened dogs and cats. The shots, which gained Food and Drug Administration approval in 2022 and 2023, respectively, are the first antibody drugs for pets. They treat osteoarthritis by targeting a protein called nerve growth factor. But vets say that could exacerbate underlying nerve conditions or other medical problems. A Wall Street Journal article is reporting that pet owners are blaming Zoetis medication for their pets' side effects, even death. However, Zoetis claims their medication is safe. The video mentions that health regulators are investigating the drugs. People who have pets that experienced side effects after taking Zoetis medication are encouraged to come forward in the comments.
Rawpetmedics - Pain management: Are Monoclonal Antibody Injections The Golden Bullet or a Poisoned Chalice?
February 6, 2024
Pain management: Are Monoclonal Antibody Injections The Golden Bullet or a Poisoned Chalice?
Journal of Feline Medicine and Surgery - Cutaneous lesions and clinical outcomes in five cats after frunevetmab injections
November 17, 2023
This case series describes five cats with cutaneous adverse events after subcutaneous administration of frunevetmab, a felinised anti-nerve growth factor monoclonal antibody, including histopathological findings in one case. All cats displayed moderate to severe pruritus resulting in self-trauma to the neck and/or head, causing lesions ranging from superficial dermatitis to alopecia and ulcerations. There were no reactions at the injection sites. In one cat, clinical signs developed after the second frunevetmab dose the cat received, with no reaction noted after the first dose. For the remaining cats, clinical signs were observed after their first dose of frunevetmab. The onset of the first episode of pruritus and self-trauma was 3–18 days after the most recent frunevetmab injection. Three cats had one or more additional frunevetmab injections after the original adverse event and all had subsequent reactions. Subsequent reactions were either similar in time frame or occurred more rapidly, with similar or more severe pruritus compared with the original reactions. Treatments and outcomes varied between cases.
Pain News Network - FDA Approves Pain Reliever for Cats Considered Too Risky for Humans
January 14, 2022
The U.S. Food and Drug Administration has approved a new medication to treat osteoarthritis pain in cats, the first monoclonal antibody drug approved by the FDA for use in any animal. The same type of drug has been rejected for use in humans because of safety risks.
2. Solensia - Media Coverage
ABC NEWS - Pet owners preparing class action against osteoarthritis drug maker over dog deaths
April 22, 2025
Olivia Mason
WHIOTV7 - 'Do your research'; Pet Owner warns others after linking cat's death to new arthritis drug
April 14, 2025
By Sharon Chen, Zoë Shriner and Andrew McMunn
WSB-TV - Pet owner warns others after linking cat’s death to new arthritis drug
November 14, 2024
Some pet owners want a recall of a new arthritis drug for cats after their animals died, some in horrific ways, just days after taking it. Full story: https://2wsb.tv/3Z8fBCg
Report24 - Cash cow of veterinary medicine: Countless dogs and cats died after "side effect-free" arthritis injection
October 16, 2024
Sickness can be used to earn money: not only in humans, but also in animals. A monoclonal antibody from the company Zoetis is sold by veterinarians as a side-effect-free miracle cure for arthritis in dogs and cats. Numerous reports of desperate pet owners show how free of side effects the remedies are: They wanted to take away the pain of their animals - and now their beloved four-legged friends are dead.
Article in German, please use translation.
Wall Street Journal (US) - What Killed Their Pets? Owners Blame Meds, but Vets Aren’t Sure
“I don’t know what cases they’re not right for. That’s something we learn over time.”
April 12, 2024
Dr. Duncan Lascelles, a professor of translational pain research and management at North Carolina State University’s College of Veterinary Medicine who helped Zoetis design Solensia studies.
3. Librela - Media Coverage, veterinary experts' insights
WITN - Popular drug used to treat dogs may come with serious risks, FDA issues warning for adverse reactions
December 16, 2024
Zoetis responds to FDA's "Dear Veterinarian Letter": “We continue to have the utmost confidence in the safety and efficacy of Librela.”
Wall Street Journal (US) - Zoetis Adds Warnings to Label for Dog-Pain Drug
February 4, 2025
Animal-health company updates label for Librela to include side effects such as seizures, paralysis.
Librela - updated product leaflet (US)
January 2025
Updated product leaflet, including FDA Letter to Veterinarian's content.
CARE - Canine Arthritis Resources and Education - Librela: What we know and don’t know
Accessed: January 2025
Comprehensive article explaining Librela.
Dr. Karen Becker - live on Librela with Rodney Habib
December 20, 2024
Before giving your pet Librela - watch this.
WSBTV - Action News - Librela Alert
December 24, 2024
WSBTV material on Librela, after FDA had issued warning Letter to Veterinarian.
Newsweek - FDA Issues Vet Letter on Drug Librela Used to Control Pain in Dogs
December 18, 2024
The Food and Drug Administration's (FDA) Center for Veterinary Medicine posted a letter to veterinarians on Monday alerting them of adverse effects reported in dogs following injections of Librela, a treatment aimed at providing pain relief for canines with osteoarthritis.
DailyMail - Warning issued after pet owners say medication is killing dogs
December 18, 2024
FDA notifies veterinarians about adverse events reported for The Food and Drug Administration (FDA) is warning vets that a popular arthritis drug for dogs could be killing people's pets.
Wall Street Journal (US) - FDA Warns About Dangers of Dog Pain Drug
December 17, 2024
Agency reviews thousands of cases of side effects, including deaths, reported for dogs that took Librela.
Today's Veterinary Business - Zoetis Responds to FDA’s ‘Dear Veterinarian’ Letter
December 16, 2024
Zoetis responds to FDA's "Dear Veterinarian Letter": “We continue to have the utmost confidence in the safety and efficacy of Librela.”
FDA - Dear Veterinarian Letter notifying veterinarians about adverse events reported in dogs treated with Librela (bedinvetmab) injection
December 16, 2024
FDA notifies veterinarians about adverse events reported for Librela.
Dr. Judy Morgan - Librela💉Pain Management for Dogs with Osteoarthritis⚠️Potential Risks & Side Effects
September 22, 2024
Dr. Morgan's view on Librela.
Vet Lessons - Librela: Hero or Villain?
September 10, 2024
Board-certified veterinary specialist Dr Mike Farrell discusses the risks and benefits of Librela, and compares the scientific research in dogs and humans.
4. Nerve Growth Factor (NGF) Articles
PubMed Central - NGF and Its Role in Immunoendocrine Communication during Metabolic Syndrome
December 19, 2022
Nerve growth factor (NGF) was the first neurotrophin described. This neurotrophin contributes to organogenesis by promoting sensory innervation and angiogenesis in the endocrine and immune systems. Neuronal and non-neuronal cells produce and secrete NGF, and several cell types throughout the body express the high-affinity neurotrophin receptor TrkA and the low-affinity receptor p75NTR. NGF is essential for glucose-stimulated insulin secretion and the complete development of pancreatic islets. Plus, this factor is involved in regulating lipolysis and thermogenesis in adipose tissue. Immune cells produce and respond to NGF, modulating their inflammatory phenotype and the secretion of cytokines, contributing to insulin resistance and metabolic homeostasis. This neurotrophin regulates the synthesis of gonadal steroid hormones, which ultimately participate in the metabolic homeostasis of other tissues. Therefore, we propose that this neurotrophin’s imbalance in concentrations and signaling during metabolic syndrome contribute to its pathophysiology. In the present work, we describe the multiple roles of NGF in immunoendocrine organs that are important in metabolic homeostasis and related to the pathophysiology of metabolic syndrome.
Boster Bio - Learn NGF/NGF Beta in 3 minutes | Beta-nerve growth factor
May 20, 2022
This is an introductory video about NGFβ, intended for scientists who need to design controls and perform immunoassays detecting NGF/NGF Beta. It contains information about western blot band size, protein expression, and interesting facts.
PAIN- Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety
October 2019
Chronic pain continues to be a significant global burden despite the availability of a variety of nonpharmacologic and pharmacologic treatment options. Thus, there is a need for new analgesics with novel mechanisms of action. In this regard, antibodies directed against nerve growth factor (NGF-Abs) are a new class of agents in development for the treatment of chronic pain conditions such as osteoarthritis and chronic low-back pain. This comprehensive narrative review summarizes evidence supporting pronociceptive functions for NGF that include contributing to peripheral and central sensitization through tropomyosin receptor kinase A activation and stimulation of local neuronal sprouting. The potential role of NGF in osteoarthritis and chronic low-back pain signaling is also examined to provide a mechanistic basis for the observed efficacy of NGF-Abs in clinical trials of these particular pain states. Finally, the safety profile of NGF-Abs in terms of common adverse events, joint safety, and nerve structure/function is discussed.
PubMed Central - NERVE GROWTH FACTOR (NGF) BLOCKADE FOR THE MANAGEMENT OF OSTEOARTHRITIS PAIN: WHAT CAN WE LEARN FROM CLINICAL TRIALS AND PRECLINICAL MODELS?
January 29, 2017
Anti-NGF antibodies hold tremendous potential for the management of osteoarthritis (OA) pain, but clinical trials have revealed serious adverse effects that are incompletely understood. This review discusses clinical trial results along with preclinical studies that have assessed NGF blockade in experimental OA, in order to provide insight for future studies.
Science Direct - Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies
January 2015
Reports of serious joint adverse events (AEs) due to osteonecrosis were noted during randomized placebo-controlled clinical trials of monoclonal antibodies to nerve growth factor (NGF), including tanezumab and fulranumab.
Journal of Translational Medicine - Nerve growth factor: from the early discoveries to the potential clinical use
November 29, 2012
The physiological role of the neurotrophin nerve growth factor (NGF) has been characterized, since its discovery in the 1950s, first in the sensory and autonomic nervous system, then in central nervous, endocrine and immune systems. NGF plays its trophic role both during development and in adulthood, ensuring the maintenance of phenotypic and functional characteristic of several populations of neurons as well as immune cells. From a translational standpoint, the action of NGF on cholinergic neurons of the basal forebrain and on sensory neurons in dorsal root ganglia first gained researcher’s attention, in view of possible clinical use in Alzheimer’s disease patients and in peripheral neuropathies respectively. The translational and clinical research on NGF have, since then, enlarged the spectrum of diseases that could benefit from NGF treatment, at the same time highlighting possible limitations in the use of the neurotrophin as a drug. In this review we give a comprehensive account for almost all of the clinical trials attempted until now by using NGF. A perspective on future development for translational research on NGF is also discussed, in view of recent proposals for innovative delivery strategies and/or for additional pathologies to be treated, such as ocular and skin diseases, gliomas, traumatic brain injuries, vascular and immune diseases.
Journal of Clinical Neuroscience - Dexamethasone enhances upregulation of nerve growth factor mRNA expression in ischemic rat brain
August 2005
Nerve growth factor (NGF) is well-established as a trophic factor that plays a crucial role in neuroregeneration and plasticity after brain insults. Dexamethasone (DEX), a powerful glucocorticoid steroid, has long been used in the clinical management of neurological disorders. We examined the relationship between NGF and DEX after an ischemic insult to the brain. In situ hybridization was used to measure NGF mRNA expression in the rat hippocampus after 20 min of transient forebrain ischemia. Immunostaining for NGF protein was performed using the avidin-biotin peroxidase method. Immunohistochemistry for glial fibrillary acidic protein (GFAP) was also used to study the astrocyte reaction in the hippocampal CA1 area. Ischemic brain from rats not treated with DEX had a 2 and 3 fold increase in NGF mRNA compared to sham-operated rats at 4 and 6 h after ischemia, respectively. The NGF mRNA expression returned to basal levels 12 h to 7 days post-ischemia. Treatment with DEX potentiated the ischemia-induced increase of NGF mRNA to 4 times that of sham-operated rats at 6 h following reperfusion and NGF protein expression was similarly elevated. Additionally, the number of GFAP positive astrocytes in the CA1 region in the ischemic rats was markedly increased. These data suggest that DEX may play a role in modulating NGF mRNA expression in the hippocampal neuronal response to brain ischemia.
The Journal of Neuroscience - Glucocorticoids differentially increase nerve growth factor and basic fibroblast growth factor expression in the rat brain
March 15, 1996
Adrenocorticotropin hormone (ACTH) and adrenal steroids may influence trophic processes operative in neuronal plasticity. Because nerve growth factor (NGF) and basic fibroblast growth factor (bFGF) participate in neuronal trophism, we have investigated whether adrenal steroids induce the expression of these two trophic factors in the rat brain. The systemic administration of dexamethasone (DEX) elicited a rapid (within 3 hr) and sustained accumulation of bFGF and NGF mRNA in the cerebral cortex and hippocampus. Regional studies showed that DEX increases bFGF but not NGF mRNA in the cerebellum, striatum, and hypothalamus. In situ hybridization studies revealed that DEX increases NGF mRNA in superficial layers of the cerebral cortex and in the dentate gyrus of the hippocampus, and bFGF mRNA throughout the brain, suggesting that DEX induces NGF mRNA in neurons and bFGF in glial cells. ACTH administered systemically elicited a temporal and regional induction in NGF and bFGF mRNA similar to that obtained with DEX. Increases in NGF and bFGF mRNAs were also observed after administration of corticosterone and, albeit to a lesser extent, aldosterone, suggesting that the pituitary-adrenocortical axis plays an important role in the regulation of NGF and bFGF expression in the brain. Our data suggest that NGF and bFGF represent a link by which the adrenal cortical system can exert trophic action on the CNS.
5. Tanezumab (Raylumis) Articles (human version of Solensia)
BioSpace - Eli Lilly and Pfizer Put Osteoarthritis Pain Drug Tanezumab Out of its Misery
October 27, 2021
The osteoarthritis drug tanezumab gets permanent leave from the market. The decision of stopping production was due to negative feedback from the regulators.
Healio - FDA panel rejects Pfizer's tanezumab for osteoarthritis pain over risk-benefit doubts
March 25, 2021
A pair of FDA advisory committees has rejected a risk mitigation proposal from Pfizer for its NGF-blocker tanezumab, stating it would fail to ensure the drug’s benefits outweigh its risks for patients with osteoarthritis.
The Motley Fool - Why Zoetis Is the Pfizer of Animal Healthcare
March 16, 2021
What makes Zoetis's business attractive is the depth and breadth of its offerings, which include vaccines, anti-infectives, and parasiticides, serving a diverse array of pet and livestock species. This wide-ranging portfolio of blockbuster drugs is built along much the same lines as that of its former parent company, Pfizer.